M icroRNAs (miRNAs) are small noncoding RNA molecules that regulate the posttranscriptional expression of target genes. [1] [2] [3] [4] There is ample evidence that miRNAs are involved in the regulation of the immune response including after transplantation. [5] [6] [7] In previous studies, we demonstrated that miR-182 was significantly increased in mononuclear cells that infiltrate rejecting allografts. 8 Furthermore, as miR-182 increases after transplant, there is a concomitant posttranscriptional decrease in the mRNA target, Forkhead box protein 1 (FOXO1). 8 Forkhead box protein 1 acts as a master cellular regulator of a variety of cellular processes and plays a critical role in the homeostasis of cells of the immune system including neutrophils, T cells, and B cells. [9] [10] [11] [12] We, and others, have demonstrated that miR-182 is induced by IL-2 and represses FOXO1 to promote clonal expansion of activated helper T lymphocytes. Expression of miR-182 is dependent on combined T-cell receptor and IL-2 signaling through STAT5. 13 Further, recent studies have demonstrated that miR-182 in increased in both antibodymediated rejection and delayed graft function of human renal allografts.
14 Because miR-182 has been demonstrated to affect T-cell responses and to be increased during graft rejection in both heart and kidney in experimental models and human transplants, we sought to further probe the role of this miRNA in alloimmune responses.
Costimulation blockade of T cell-antigen-presenting cell responses has been identified as an effective treatment strategy for a variety of conditions. [15] [16] [17] [18] Biologics that target either CTLA-4 (monoclonal antibody human IgG1, Ipilimumab) or CD80/CD86 (recombinant fusion protein CTLA-4 human IgG1, Abatacept or Belatacept) are being successfully used for metastatic melanoma, rheumatoid arthritis, and renal transplantation, respectively. [19] [20] [21] [22] [23] We now demonstrate that combined costimulation blockade and absence of miR-182 is superior to costimulation blockade alone, in decreasing alloimmune T cell responses, leading to a significant prolongation of allograft survival. Thus, our findings demonstrate a role for miR-182 in T-cell activation during allograft rejection.
MATERIALS AND METHODS

Animals and Transplantation Model
Ten-week-old C57BL/6 and BALB/c mice were purchased from Charles River Laboratories (Hollister, CA). B6.129SH2 dlAb1-Ea and B6.129S2-Tap1 tm1Arp mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Homozygous miR-182 deficient mice (miR-182
) on the C57BL/6 background were obtained from Dr. Iwai, National Cerebral and Cardiovascular Center, Japan 24 and confirmed in our hands to not express miR-182 (data not shown). All experimental procedures were performed in accordance with a Stanford Institutional Animal Care and Use Committee-approved protocol. Heterotopic heart transplantation was performed in groups (n = 4-8; see specific experiments) of syngeneic C57BL/6→C57BL/6 and allogeneic BALB/c→C57BL/6; (wildtype, WT) BALB/c→miR-182
and, BALB/c→B6.129S2-Tap1 tm1Arp mice as reported previously. 25 Some groups of recipients were treated with CTLA4-Ig (Abatacept, a gift from Bristol Myers Squibb) at dose of 0.5 mg intraperitoneal on day 0, followed by a dose of 0.25 mg on days 2, 4, and 6. Function of the grafts was assessed through abdominal palpation and confirmed by histopathological analyses using H&E and Masson Trichrome staining.
Cell Isolation and Purification
Splenocytes were isolated from transplant recipients on day 5, day 7, or day 28 posttransplant. Peripheral blood mononuclear cells and graft infiltrating lymphocytes (GILs) were isolated from blood and heart grafts, respectively, on day 5 posttransplant as described previously. 8 To isolate GILS, grafts were perfused with phosphate buffered saline before recovery. After removal, the cardiac tissue was minced and placed in Roswell Park Memorial Institute medium 1640 containing collagenase (2 mg/mL), incubated at 37°C for 2 hours and strained through a 70-μm nylon cell strainer. Graft infiltrating lymphocytes were purified using Lympholyte (Cedarlane, Ontario, Canada) before RNA extraction as described previously. 8 PBMC were isolated from graft recipients using lympholyte. CD4 + T cells were enriched from spleens of mice using EasySep mouse CD4 + T-cell isolation kit (Stemcell Technologies, BC, Canada). B cells were isolated from spleens of mice using EasySep mouse B cell-negative isolation kit (Stemcell Technologies).
CD4 + T Cell Activation
Purified CD4 + T cells (2 x 10 5 cells/well) were plated in 96-well plates precoated with 5 μg/mL anti-CD3 Ab (eBioscience, San Diego, CA), then soluble anti-CD28 Ab (eBioscience) was added (final concentration, 2 μg/mL). Cells were cultured for 48 hours and the collected for RNA isolation. by TaqMan miRNA assays (Applied Biosystems, Carlsbad, CA). SnoRNA202 expression was used for normalization.
To determine the expression of mouse IFN-γ, IL-2, and β-actin, cDNA was synthesized from total RNA samples using SuperScript II reverse transcriptase with random hexamers (Invitrogen, Carlsbad, CA). Real-time PCR was performed using iQ SYBR Green Supermix (Bio-rad, Hercules, CA). The primers were as follows (forward and reverse primers): mouse IFN-γ: 5′ CAG CAA CAA CAT AAG CGT CAT 3′ and 5′ ACC TCA AAC TTG GCA ATA CTC 3′; mouse IL-2: 5′ GGC ATG TTC TGG ATT TGA CT 3′ and 5′ TCATCATCG AAT TGG CAC TC 3′; mouse β-Actin: 5′ CAG CCT TCC TTC TTG GGT AT 3′, and 5′ GGT CTT TAC GGA TGT CAA CG 3′.
Flow Cytometry
Splenocytes were collected and washed with cold flow cytometry buffer (PBS, 1% FBS, 0.1% sodium azide) before staining with immunofluorescent markers. Briefly, 2 Â 10 6 cells were incubated with 0.5 μL LIVE/DEAD Fixable Aqua Dead Cell Stain (Thermofisher Scientific, Waltham, MA) and incubated for 15 to 20 minutes on ice. Cells were then labeled with the following antibodies (as per manufacturer's instructions): FITC rat antimouse CD44 mAb, PE rat antimouse CD4 mAb (BD PharMingen, San Diego, CA); and BV570 rat antimouse CD4 mAb, BV785 rat antimouse CD44 mAb and Alexa700 rat anti-mouse CD62L mAb (Biolegend, San Diego, CA). FITC rat IgG2b, k mAb, and PE rat IgG2a, k mAb (BD PharMingen); and BV570 rat IgG2a k mAb, BV785 Rat IgG2b k mAb and Alexa700 rat IgG2a k mAb (Biolegend) were used as isotype controls. Cells were washed twice with cell staining buffer (Biolegend), resuspended in 200 μL of cell staining buffer and analyzed on FACScan flow cytometer or LSR II.2 (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo software (Tree Star, Ashland, OR).
FOXO1 Quantitation
Protein was extracted from splenocytes using Cell Extraction Buffer (Invitrogen, Carlsbad, CA) containing 1.0 mM Phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor cocktail (Sigma, St. Louis, MO). The following antibodies were used: rabbit anti-mouse FOXO1 mAb (clone C29H4; Cell Signaling Technology, Beverly, MA), anti-β-Actin mAb (clone AC-15, Sigma), donkey antirabbit, and donkey antimouse IgG antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Blots were visualized with SuperSignal West Pico Substrate (Thermofisher Scientific), and quantification was performed using ImageJ software (NIH, Bethesda, MD).
Immunohistochemistry
Infiltrating CD4
+ or CD8 + cells in heart grafts were detected by immunofluorescence as described previously. 8 Rat antimouse CD4 mAb (clone GK1.5) or rat antimouse CD8 mAb (clone 53-6.7) (eBioscience) were used as primary Abs. Alexa Fluor 488 goat anti-rat IgG (H + L) mAb was used as secondary Ab (Invitrogen, Carlsbad, CA). 4′,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) was used to label nuclei. Representative images (63Â magnification) were photographed using a digital camera attached to a Zeiss LSM 510 META inverted laser scanning confocal microscope (Zeiss, Oberkochen, Germany). Infiltrating cells were counted in different fields of vision (7-12 fields) using ImageJ software (NIH).
Statistical Analysis
All of the data are presented as mean ± SEM. GraphPad Prism software was used for generating Kaplan-Meier survival curves and data analysis using Student t test, and P values less than 0.05 were considered statistically significant.
RESULTS
T Cells Are the Cellular Source of miR-182 During Alloimmune Responses
Previously, we have demonstrated that cells that infiltrate rejecting cardiac allograft express miR-182. 8 Further, miR-182 was increased in both the PBMC and splenocytes isolated from recipients of cardiac allografts (BALB/C→C57BL/6) as compared with syngeneic (C57BL/6→C57BL/6) grafts on day 7 posttransplant indicating that miR-182 is increased both within the allograft and the periphery during graft rejection ( Figure S1 , SDC and SDC, Materials and Methods, http://links.lww.com/TP/B311). These findings support a role for miR-182 in regulating immune cell functions during allograft rejection. To define the role of miR-182 in graft rejection, groups (n = 5) of WT C57BL/6 or miR-182 −/− mice received cardiac grafts from BALB/c mice and were monitored for graft survival. miR-182 −/− recipients had a modest yet statistically significant, 2-day prolongation of graft survival (6.4 days vs 8.2 days, P < 0.01; Figure 1A ). To establish the cellular source of miR-182, BALB/c hearts were transplanted into B6.129S-H2 (MHC I − and CD8 + T cell-deficient) or C57BL/6 recipients (n = 4 per group) and miR-182 levels in PBMC and GILs quantitated on day 5 posttransplant. As expected, and consistent with our previous studies, 8 expression of miR-182 was increased significantly in both the PBMC and GILs of C57BL/6 recipients of allografts as compared with recipients of syngeneic grafts ( Figure 1B ). In PBMC from B6.129S2-Tap1 tm1Arp recipients, the miR-182 levels were similar to that seen in the control allogeneic transplant group of wild-type C57BL/6 recipients indicating that miR-182 was still elevated in the absence of CD8 + T cells. In contrast, in B6.129S-H2 dlAb1-Ea recipients that lack CD4 + T cells, miR-182 expression was similar to that detected in the syngeneic transplant group. When GILs were analyzed, there was a similar significant decrease in miR-182 in the absence of CD4 + T cells but the levels of miR-182 were increased over syngeneic suggesting a cell type other than a CD4 + T was also expressing miR-182. We have now added an additional, complementary, approach where we isolated B and T cells from the spleens of syngeneic and rejecting recipients of cardiac allografts and quantitated miR-182 by q-RT-PCR (SDC, Materials and Methods, http://links.lww.com/TP/B311). We clearly demonstrate that all the enhanced miR-182 is from T cells and not from B cells ( Figure S2 , SDC, http://links.lww.com/TP/B311). Taken together, these results support that miR-182 expression is dependent on the presence of T cells and suggest that CD4 + T cells are the major cellular source of miR-182 during alloactivation.
miR-182 Contributes to Optimal T-Cell Activation and IFN-γ Expression
To understand the role of miR-182 in T cell function, purified CD4 + T cells were isolated from C57BL/6 mice and activated with anti-CD3 and anti-CD28 antibodies. Forty-eight hours after activation, miR-182 and IFN-γ mRNA were significantly increased in CD4 + T cells (Figures 2A and B , respectively). However, in the absence of miR-182, IFN-γ was significantly decreased as compared with WT controls, suggesting that miR-182 contributes to optimal, IFN-γ production by CD4 + T cells ( Figure 2B ). dlAb1-Ea (MHC II and CD4 + T cell-deficient) and B6.129S2-Tap1 tm1Arp (MHC I and CD8 + T cell-deficient) recipients. C57BL/6 hearts transplanted into C57BL/6 recipients were used as controls. PBMC and GILs were obtained from recipients on day 5 posttransplant, and miR-182 expression was detected by quantitative RT-PCR. Expression fold changes of miR-182 were calculated by the 2 -ΔΔCt method, normalized to the expression of housekeeping gene snoRNA202 and expression fold changes normalized to the control group. Data shown are the mean ± standard error of all graft recipients (*P < 0.05, **P < 0.01, or ***P < 0.001).
CTLA4-Ig Inhibits miR-182 Expression and Alters the Alloimmune Response
To further understand the relationship between miR-182 expression and T-cell activation after transplantation, groups of C57BL/6 recipients received BALB/c heart allografts with or without CTLA4-Ig treatment. CTLA4-Ig blocks the CD28/ CTLA4 ligands CD80 and CD86, thus inhibiting costimulation between T cells and antigen-presenting cells. As expected, on day 7 posttransplant, the number of CD4 + T cells was significantly increased in recipients of heart allografts that did not receive CTLA4-Ig, with CD4 lo T cells in either allogeneic transplant groups, without or with CTLA4-Ig treatment, which were not elevated after transplantation as compared with control group. Further, on day 7 posttransplant, miR-182 was significantly increased in splenocytes from mice that received allografts ( Figure 3B , grey bars). Treatment with CTLA4-Ig significantly decreased miR-182 expression ( Figure 3B , black bars). Because CTLA4-Ig treatment alters miR-182 expression and FOXO1 is a target of miR-182, 8 we determined if FOXO1 protein levels were modulated after transplant in recipients treated with CTLA4-Ig ( Figure 3C ). Splenocytes from graft recipients treated with CTLA4-Ig had significantly more FOXO1 that untreated allograft recipients consistent with a concomitant decrease in miR-182 and increase of the FOXO1 protein. Taken together, these studies indicate that CTLA4-Ig results in a decrease in CD4   +   CD44 hi T cells, decreased levels of miR-182 and a significant increase in the transcription factor, FOXO1.
Absence of miR-182 Augments Efficacy of CTLA4-Ig Treatment Posttransplant
Since the absence of miR-182 prolonged graft survival, we then asked whether costimulation blockade would further prolong graft survival in the absence of miR-182. Groups of WT C57BL/6 (n = 7) or miR-182 −/− (n = 8) recipients of BALB/c hearts were treated with CTLA4-Ig and graft survival monitored. In WT, CTLA4-Ig-treated C57BL/6 recipients, graft survival was significantly increased to a mean of over 30 days as compared with 7 days in untreated WT C57BL/6 recipients (see Figure 1A for comparison). Graft survival was further prolonged (mean of 60.0 days miR-182 −/− vs 30.5 days WT, P < 0.01) in the absence of miR-182 ( Figure 4A ). Splenocyte lysates analyzed by Western blot demonstrated that FOXO1 protein levels were significantly increased in mice deficient in miR-182
, that had significantly prolonged graft survival, as compared with WT C57BL/6 recipients of ( Figure 4B ) consistent with the finding that graft survival is enhanced in the presence of increased levels of FOXO1 protein.
Sections of the cardiac allografts were examined at 28 days posttransplant, a timepoint when graft survival was 100% in the miR-182 −/− CTLA4-Ig-treated group. Both CD4 + T and lo T cells in the spleen were quantitated, by flow cytometry on day 7 posttransplant. B, miR-182 expression was quantitated in splenocytes as detailed previously and compared to control C57BL/6 mice. C, Lysates were prepared from splenocytes and FOXO1 protein levels determined by Western blot (upper panel) with the densitometry of the ratio of FOXO1 to β-actin shown below (lower panel). Data represent mean ± standard error of the mean (*P < 0.05; **P < 0.01).
CD8
+ T cells were decreased (CD4 + T cells, 42.9 ± 13.1%, P < 0.05; CD8 + T cells, 36.9 ± 12%, P = 0.08) in miR-182
allograft recipients as compared with WT C57BL/6 allograft recipients (Figures 4C and D) . The observation that both CD4 + and CD8 + T cells were reduced in the heart grafts of miR-182 −/− recipients suggest that miR-182 regulation of FOXO1 (increased FOXO1 as a result of the lack of miR-182) reduces the infiltration of lymphocytes into allografts leading to reduced inflammatory response and prolonged graft survival. 
DISCUSSION
We demonstrated previously that miR-182 was dramatically increased during rejection and specifically detected in the circulation of allograft recipients. 8 The IL-2-miR-182 Because activation of T cells results in increased miR-182 and a concomitant decrease in the transcription factor FOXO1, we asked whether blockade of costimulatory pathways alters miR-182 levels. Indeed, we clearly show that in the presence of CTLA4-Ig, miR-182 in decreased in T cells while increasing FOXO1 protein production. CTLA4, a member of the immunoglobulin superfamily, is expressed on the surface of T cells and transmits an inhibitory signal. Specifically, CTLA4 competes with CD28 for binding to CD80 and CD86 and while CD28 transmits a stimulatory signal, CTLA4 suppresses T cell function. 26 Indeed, 2 pharmacologically modified forms of CTLA4-Ig, belatacept, and abatacept are FDA approved for treatment of kidney transplantation and rheumatoid arthritis, respectively. 27, 28 Treatment with CTLA4-Ig dramatically and significantly prolonged cardiac allograft survival in mice-deficient in miR-182; 50% of the allografts survived more than 60.0 days as compared to 30.5 days in mice expressing miR-182, suggesting a role for miR-182 in graft rejection. Analysis of human renal allograft biopsies demonstrated that increased expression of miR-182 is associated with both antibody-mediated rejection and acute kidney injury. 14, 29 Our studies, and others, have demonstrated FOXO1 as a target of miR-182 and indeed FOXO1 was significantly increased in miR-182 −/− recipients of cardiac allografts treated with CTLA4-Ig supporting a role for FOXO1 in graft survival. 8, 13, 30 Forkhead box protein 1 suppresses proliferation of resting CD4 + T cells by upregulating the expression of a Cdk inhibitor, p27Kip1. + T-cell compartment we observed in the CTLA4-Igtreated miR-182 −/− graft recipients. Previous studies have also shown that the levels of FOXO1 impact lymphocyte infiltration. 33 Mice with a deletion of FOXO1 in T cells were shown to have increased infiltration of T cells and enhanced Tfh cell differentiation. 11 Consistent with this finding, we show that there is a significant reduction in CD4 + T cells (and a marked trend toward decreased numbers of CD8 + T cells) in CTLA-4Ig-treated miR-182 −/− mice as compared with miR-182-expressing mice supporting that an increase of FOXO1 is associated with a decrease of lymphocyte infiltration.
Computational analysis identified miR-182 in Th2-Foxp3 + cells as a potential regulatory miRNA hub. 34 Further, it was shown that regulatory T cells isolated from Th2 environments after chronic Schistosoma mansoni infection or Th2-driven inflammation downregulated IL-2-associated genes under the control of miR-182. 35 No differences in regulatory T cell numbers (CD4 + CD25 + FoxP3 + T cells) were observed in the absence or presence of miR-182 in our (Th1-mediated) model of cardiac allograft rejection (BALB/c to miR-182−/− + CTLA-4Ig, 4.54 ± 0.54 vs BALB/c to C57BL/6 + CTLA-4Ig, 4.59 ± 0.28; P < 0.9302). Although a recent study suggested that the immune response to experimental Listeria monocytogenes infection is intact in miR-182 −/− mice, 36 our results, using miR-182 −/− on the same C57BL/6 background, do suggest some alterations on the early immune response after cardiac allograft transplantation. Further, the recent studies of Li et al 37 demonstrate that miR-182 deficiency (using knockout mice) does impair early T cell-dependent immune responses. Taken together, these studies suggest that miR-182 does have a role in T-cell function, early after stimulation, but suggest that after chronic stimulation/exposure, the malleability of the miR networks may compensate for the loss of specific microRNAs.
In summary, we have reported for the first time the synergistic effect of the absence of a specific miRNA and costimulation blockade on cardiac allograft survival. Further, our results support a mechanism whereby modulation of FOXO1 may be at least partially responsible for the immune alterations that prolong graft survival. Blockade of selective miRNAs may prove to be an efficacious strategy to inhibit the alloimmune response after transplant.
